¿Cómo paga?
¿Qué concentración? Elija la suya
¿Cuántas tabletas?

Cómo pagar lo menos posible

Desde

$13 por 30 tabletas

Tamoxifen genérico de Rx Outreach, por correo. Elija la concentración de su etiqueta para ver su precio.

Qué hacer

  1. Cree una cuenta gratis en rxoutreach.org. Pídale a su médico que mande la receta allí, o Rx Outreach puede transferirla.Ir a Rx Outreach 
  2. Pida tamoxifen genérico. Le llega por correo.

Otras opciones

¿Lo necesita hoy? Desde $15.30 por 30 tabletas con la Team Cuban Card gratis, en farmacias que la aceptan. Obtenga la tarjeta gratis y muéstrela allí.

Ver el precio y obtener la tarjeta 

La FDA califica el tamoxifen de cada compañía para que funcione igual, así que cualquier farmacia puede surtir su receta con el que tenga.

Vea el precio de cada farmacia

Dónde comprarlo

Precios sin seguro que publica cada farmacia para tamoxifen genérico, del más bajo al más alto.

Recoger en tiendaEnvío

Del sitio web de cada farmacia, consultado el 17 de noviembre de 2026. Confirme el precio antes de surtir su receta.

Sobre estos precios

Los precios cambian, pueden variar según la tienda y el estado, y pueden depender de la concentración y de cuántas toma. Si tiene seguro, pregunte cuánto le cobra su plan; puede ser menos.

Quién lo fabrica

4 compañías venden tamoxifen en esta forma, y la FDA califica a cada una como sustituto de las demás. La farmacia surte la que tenga. Para recibir el de un fabricante en particular, pídalo por su nombre; la mayoría de las farmacias lo pueden pedir en uno o dos días.

  • Actavis Pharma10 mg, 20 mg

    Contiene lactosa

    Cómo se ve, qué contiene, NDC

    10 mg Blanca, redonda, 8 mm, marcada con “2232 / WPI”

    EmpaqueNDC
    Frasco de 600591-2472-60
    Frasco de 1800591-2472-18

    20 mg Blanca, redonda, 10 mm, marcada con “2233 / WPI”

    EmpaqueNDC
    Frasco de 300591-2473-30
    Frasco de 900591-2473-19

    Ingredientes inactivos (en inglés, como en la etiqueta): croscarmellose sodium, lactose monohydrate, magnesium stearate, cellulose, microcrystalline, starch, corn

    Etiqueta de la FDA

  • Aurobindo Pharma10 mg, 20 mg

    Contiene lactosa · Fabricado por Eugia Pharma Specialities

    Página del producto en aurobindousa.com

    Cómo se ve, qué contiene, NDC

    10 mg Blanca a blanquecina, redonda, 7 mm, marcada con “T10”

    EmpaqueNDC
    Frasco de 6059651-299-60

    20 mg Blanca a blanquecina, redonda, 9 mm, marcada con “T20”

    EmpaqueNDC
    Frasco de 3059651-300-30
    Frasco de 9059651-300-90

    Ingredientes inactivos (en inglés, como en la etiqueta): starch, corn, croscarmellose sodium, hypromellose 2910 (5 mpa.s), lactose monohydrate, magnesium stearate, polyethylene glycol 400, povidone k30, titanium dioxide

    Etiqueta de la FDA

  • Dr. Reddy’s Laboratories10 mg, 20 mg

    Contiene lactosa

    Cómo se ve, qué contiene, NDC

    10 mg Blanca, redonda, 7 mm, marcada con “MYX / 642”

    EmpaqueNDC
    Frasco de 6075907-058-60
    Frasco de 100075907-058-10

    20 mg Blanca, redonda, 9 mm, marcada con “MYX / 643”

    EmpaqueNDC
    Frasco de 3075907-059-30
    Frasco de 100075907-059-10

    Ingredientes inactivos (en inglés, como en la etiqueta): croscarmellose sodium, lactose monohydrate, magnesium stearate, hypromellose 2910 (5 mpa.s), polyethylene glycol 400, povidone k30, starch, corn, titanium dioxide

    Etiqueta de la FDA

  • Mylan Pharmaceuticals10 mg, 20 mg

    Contiene lactosa · Se está dejando de vender; disponible hasta abril de 2027

    Página del producto en viatris.com

    Cómo se ve, qué contiene, NDC

    10 mg Blanca, redonda, 7 mm, marcada con “M / 144”

    EmpaqueNDC
    Frasco de 600378-0144-91

    20 mg Blanca a blanquecina, redonda, 10 mm, marcada con “M / 274”

    EmpaqueNDC
    Frasco de 300378-0274-93

    Ingredientes inactivos (en inglés, como en la etiqueta): anhydrous lactose, silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate

    Etiqueta de la FDA

Quién lo vende: registros de la FDA y de Medicaid, actualizados cada semana. La página, la tarjeta y el programa de cada fabricante vienen de su propio sitio web.

Qué decir en la farmacia

“Antes de surtirla, ¿cuánto pagaría por tamoxifen genérico?”

¿Paga sin seguro? Pregunte el precio sin seguro. Con seguro, pregunte cuánto cobra su plan.

Para qué se usa

Lo que dice la etiqueta de la FDA (en inglés)

Metastatic Breast Cancer

Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen citrate tablets are an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen citrate tablet therapy.

Adjuvant Treatment of Breast Cancer

Tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some tamoxifen adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes.

Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation.

The estrogen- and progesterone-receptor values may help to predict whether adjuvant tamoxifen citrate tablet therapy is likely to be beneficial.

Tamoxifen citrate tablets reduce the occurrence of contralateral breast cancer in patients receiving adjuvant tamoxifen citrate tablet therapy for breast cancer.

Ductal Carcinoma in Situ (DCIS)

In women with DCIS, following breast surgery and radiation, tamoxifen citrate tablets are indicated to reduce the risk of invasive breast cancer (see BOXED WARNING). The decision regarding therapy with tamoxifen citrate tablets for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen citrate tablet therapy.

Current data from clinical trials support 5 years of adjuvant tamoxifen citrate tablet therapy for patients with breast cancer.

Reduction in Breast Cancer Incidence in High Risk Women

Tamoxifen citrate tablets are indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration with a median follow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. The longer-term effects are not known. In this study, there was no impact of tamoxifen citrate tablets on overall or breast cancer-related mortality (see BOXED WARNING).

Tamoxifen citrate tablets are indicated only for high risk women. "High risk" is defined as women at least 35 years of age with a 5 year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model.

Examples of combinations of factors predicting a 5 year risk ≥ 1.67% are:

Age 35 or older and any of the following combination of factors:

  • One first-degree relative with a history of breast cancer, two or more benign biopsies, and a history of a breast biopsy showing atypical hyperplasia; or
  • At least two first-degree relatives with a history of breast cancer, and a personal history of at least one breast biopsy; or
  • LCIS

Age 40 or older and any of the following combination of factors:

  • One first-degree relative with a history of breast cancer, two or more benign biopsies, age at first live birth 25 or older, and age at menarche 11 or younger; or
  • At least two first-degree relatives with a history of breast cancer, and age at first live birth 19 or younger; or
  • One first-degree relative with a history of breast cancer, and a personal history of a breast biopsy showing atypical hyperplasia.

Age 45 or older and any of the following combination of factors:

  • At least two first-degree relatives with a history of breast cancer and age at first live birth 24 or younger; or
  • One first-degree relative with a history of breast cancer with a personal history of a benign breast biopsy, age at menarche 11 or less and age at first live birth 20 or more.

Age 50 or older and any of the following combination of factors:

  • At least two first-degree relatives with a history of breast cancer; or
  • History of one breast biopsy showing atypical hyperplasia, and age at first live birth 30 or older and age at menarche 11 or less; or
  • History of at least two breast biopsies with a history of atypical hyperplasia, and age at first live birth 30 or more.

Age 55 or older and any of the following combination of factors:

  • One first-degree relative with a history of breast cancer with a personal history of a benign breast biopsy, and age at menarche 11 or less; or
  • History of at least two breast biopsies with a history of atypical hyperplasia, and age at first live birth 20 or older.

Age 60 or older and:

  • 5 year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model.

For women whose risk factors are not described in the above examples, the Gail Model is necessary to estimate absolute breast cancer risk. Healthcare Professionals can obtain a Gail Model Risk Assessment Tool by dialing Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX).

There are insufficient data available regarding the effect of tamoxifen citrate tablets on breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of tamoxifen in these patients.

After an assessment of the risk of developing breast cancer, the decision regarding therapy with tamoxifen citrate tablets for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen citrate tablet therapy. In the NSABP P-1 trial, tamoxifen citrate tablet treatment lowered the risk of developing breast cancer during the follow-up period of the trial, but did not eliminate breast cancer risk (see CLINICAL PHARMACOLOGY: Table 3).

Fuente: la etiqueta de la FDA de Tamoxifen (Mylan Pharmaceuticals Inc.), 2 de julio de 2021. Etiqueta completa en DailyMed 

Datos útiles

  • El tamoxifen de distintas compañías puede verse diferente. La FDA exige que todos funcionen igual.
  • No deje ni cambie un medicamento sin hablar con su farmacéutico o su médico.